28 / 41
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 82
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Relationships between serum adipokine levels (adiponectin, leptin) in diabetic and non-diabetic
osteoporosis patients
Javad Mohiti-Ardekani
1
, Reza Didehdar
1
, Zahra Sadat Rouhani
2
and
Hosein Soleymani-Salehabadi
1
1
Shahid Sadoughi University of Medical Sciences, Iran
2
Payam-e-Noor University of Taft, Iran
T
he purpose of this study was to investigate the relationship between serum adipokine levels (adiponectin, leptin) in
diabetic and non-diabetic osteoporosis patients. We studied 72 osteoporosis patients (36 diabetic and 36 non-diabetic with
body mass index [BMI] 28.1±5.1 and 27.1±6.8, respectivety). BMD was studied by dual-energy X-ray absorptiometry from
the lumbar spine (L1–L4) and femoral neck and fasting blood samples were taken for biochemical measurement of fasting
blood glucose, Glycosylated hemoglobin, leptin, adiponectin. Fasting levels of plasma adiponectin had a significant positive
correlation with BMD of the lumbar spine and a no significant positive correlation with BMD of the femoral neck in the
diabetic osteoporosis group (r=0.9, P=0.02/r=0.18, P=0.31, respectively) , but a no significant negative correlation with BMD
of the femoral neck and lumbar spine in the non-diabetic osteoporosis group (r=-0.02, P=0.95/r=-0,01, P=0.95, respectively).
Leptin did not have a significant correlation with BMD in either the diabetic and non-diabetic osteoporosis groups (P>0.05).
The correlation between adiponectin and leptin are not inconclusive.
mohiti@ssu.ac.ir mohoti_99@yahoo.comClin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026